SEC Form 4 · accession 0000947871-26-000881

Electra Therapeutics, Inc. · ETRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Carl L Gordon

Director · 10% Owner

Period of report

Sep 21, 2026

Accepted (ET)

Sep 23, 2026 · 5:35 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0002088082

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F3,F5	Sep 21, 2026	C	2,002,310	—	A	2,002,310	I	See footnotes
Common Stock^F1,F3,F5	Sep 21, 2026	C	1,087,934	—	A	3,090,244	I	See footnotes
Common Stock^F1,F3,F5	Sep 21, 2026	C	1,703,314	—	A	4,793,558	I	See footnotes
Common Stock^F2,F3,F5	Sep 21, 2026	P	333,333	$15.00	A	5,126,891	I	See footnotes
Common Stock^F1,F4,F5	Sep 21, 2026	C	758,279	—	A	758,279	I	See footnotes
Common Stock^F2,F4,F5	Sep 21, 2026	P	1,000,000	$15.00	A	1,758,279	I	See footnotes

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Convertible Preferred Stock^F3,F5,F1	—	Sep 21, 2026	C	2,002,310	D	—	—	Common Stock	2,002,310	I
Series B Convertible Preferred Stock^F3,F5,F1	—	Sep 21, 2026	C	1,087,934	D	—	—	Common Stock	1,087,934	I
Series C Convertible Preferred Stock^F3,F5,F1	—	Sep 21, 2026	C	1,703,314	D	—	—	Common Stock	1,703,314	I
Series C Convertible Preferred Stock^F4,F5,F1	—	Sep 21, 2026	C	758,279	D	—	—	Common Stock	758,279	I

Explanation of responses

F1Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering on September 21, 2026 without payment of further consideration. The Preferred Stock has no expiration date.
F2Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
F3These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
F4These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
F5Each of the Reporting Person, OrbiMed Advisors, GP VII and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.